# Colesevelam for Children With Type 2 Diabetes

Study · id `cardio:ct-nct01258075` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01258075](<https://clinicaltrials.gov/study/NCT01258075>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01258075

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 236 participants.

## Technical summary

Registry record NCT01258075. Randomized; double masking; primary purpose treatment. Start 2011-02-24 (actual); primary completion 2019-11-01 (actual). Results posted on 2020-12-22.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 236 participants (enrolled count; ClinicalTrials.gov record NCT01258075, source copy `cardio:ctgov-nct01258075-2021-05-13`, retrieved 2026-10-26)
- Started: 2011-02-24 (actual) (ClinicalTrials.gov record NCT01258075, source copy `cardio:ctgov-nct01258075-2021-05-13`, retrieved 2026-10-26)
- Primary completion: 2019-11-01 (actual) (ClinicalTrials.gov record NCT01258075, source copy `cardio:ctgov-nct01258075-2021-05-13`, retrieved 2026-10-26)
- Completion: 2020-04-21 (actual) (ClinicalTrials.gov record NCT01258075, source copy `cardio:ctgov-nct01258075-2021-05-13`, retrieved 2026-10-26)
- Results first posted: 2020-12-22 (ClinicalTrials.gov record NCT01258075, source copy `cardio:ctgov-nct01258075-2021-05-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01258075, source copy `cardio:ctgov-nct01258075-2021-05-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01258075-2021-05-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Colesevelam for Children With Type 2 Diabetes
- Acronym: WELKid DM
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): High-dose colesevelam
- Intervention (Drug): Low-dose colesevelam
- Lead sponsor: Daiichi Sankyo
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Daiichi Sankyo (`cardio:org-daiichi-sankyo`)

## Provenance

Content hash: 0bdc3123997c4f58d25f8c9096dab7785e3a5268e25d221056c04d28c3176d1f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
